Global Registry Data Confirms Survival Advantage of Mogamulizumab in Advanced Cutaneous T-Cell Lymphoma
核心洞察
New findings from the PROCLIPI study, spanning 19 countries and over 2,000 patients, demonstrate a meaningful overall survival advantage for advanced cutaneous T-cell lymphoma (搜索) patients treated with mogamulizumab.
Among 371 patients with advanced mycosis fungoides (搜索) and Sézary syndrome (搜索), those receiving mogamulizumab showed median overall survival of 64 months compared to 54 months for those not receiving the therapy.
For Sézary syndrome (搜索) patients specifically, median survival reached approximately 6.5 years with mogamulizumab treatment versus 3 years for those on other systemic treatments.
New findings from the PROgnostic Cutaneous Lymphoma International Prognostic Index (PROCLIPI) Study provide compelling evidence that mogamulizumab offers a meaningful overall survival advantage for patients with advanced cutaneous T-cell lymphoma (搜索) (CTCL), including mycosis fungoides (搜索) (MF) and Sézary syndrome (搜索) (SS). The analysis, presented at the European Organization for Research and Treatment of Cancer's 2025 Cutaneous Lymphoma Tumor Group Annual Meeting in Athens, Greece, adds substantial weight to emerging real-world data supporting this therapeutic approach.
Significant Survival Benefits Demonstrated
Among 371 patients with advanced MF and SS, the study reported a median overall survival (OS) of 64 months for those treated with mogamulizumab, compared with 54 months for patients who did not receive the therapy (p<0.01). The survival advantage was even more pronounced in the subgroup of patients with Sézary syndrome (搜索), where median OS reached approximately six-and-a-half years for those given mogamulizumab versus three years for those on other systemic treatments (p<0.01).
The therapy, marketed under the brand name Poteligeo by Kyowa Kirin International (搜索) (KKI), demonstrated consistent benefits across the patient population studied. Of the 371 patients analyzed, 72 received mogamulizumab treatment while 175 did not receive the therapy. In the Sézary syndrome (搜索) subset of 96 patients, the survival difference was particularly striking.
Global Collaboration Powers Rare Disease Research
The PROCLIPI registry represents one of the largest international efforts in CTCL research, spanning 19 countries and including more than 2,000 patients. The registry was established to generate robust prognostic data for CTCL subtypes and now provides one of the most comprehensive views of global outcomes in this rare disease area.
"The PROCLIPI Study demonstrates the power of global collaboration in rare diseases," said Professor Julia Scarisbrick, chief investigator of the PROCLIPI Study and honorary professor of dermatology at University Hospitals Birmingham NHS Foundation Trust. "By bringing together data from across the world, we can generate insights that simply wouldn't be possible in isolation."
Real-World Evidence Complements Clinical Trials
Now in its tenth year, PROCLIPI collects extensive data encompassing clinical, pathological, imaging, and treatment parameters to refine prognostic understanding of MF and SS. A recently developed Cutaneous Lymphoma International Prognostic Index (CLIPI) has introduced a more precise system for risk stratification, enabling researchers and clinicians to identify which patient subgroups are most likely to benefit from specific therapies.
These results underscore the importance of real-world data in complementing clinical trials for rare malignancies, where limited patient populations can constrain traditional study designs. Such large-scale registries are increasingly shaping biopharmaceutical strategies for rare diseases by bridging gaps between controlled trials and real-world patient experiences.
Clinical Impact and Future Implications
"These insights into improved overall survival for patients living with CTCL mark an important step forward, providing a stronger clinical evidence base and reinforcing the value of international networks in rare disease research," said Dr. Nick Kronfeld, head of medical affairs, Kyowa Kirin International (搜索).
The partnership between KKI and University Hospitals Birmingham NHS Foundation Trust exemplifies how industry and academia can jointly advance understanding of rare cancers through real-world evidence generation. For patients and families affected by CTCL, these findings represent more than statistical improvements.
"For those of us in the CTCL community, survival isn't just about numbers on a chart—it's about being able to spend more time with our families, plan for the future, and live life with dignity," said Susan Thornton, CEO, Cutaneous Lymphoma Foundation (搜索).
As biologics and targeted therapies continue to evolve, integrating longitudinal registry data with molecular profiling and treatment outcomes may accelerate development pathways for other low-prevalence malignancies. For manufacturers, this type of data-driven insight not only refines understanding of therapeutic benefit but also informs production planning, clinical trial design, and health policy frameworks that enable better access for patients worldwide.